Kindred to scale back animal research

Can an animal health company cut back on expenses by cutting back on animal testing? California's Kindred Biosciences ($KIN) is set to ramp up its operations by doing exactly that. The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year. Kindred this week reported its Q1 earnings and announced it's on track with its CereKin pivotal study, its doggy drug for osteoarthritis, based off studies for Amgen ($AMGN) and Pfizer's ($PFE) Enbrel. Release

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.